Focus on Neurology and Psychiatry   /     Staying Ahead of Progression in RMS

Shownotes

Guest: Timothy William West, MD

Here to discuss staying ahead of progression in patients with relapsing multiple sclerosis (RMS) is Dr. Timothy William West. Dr. West walks us through pathophysiological changes in progressing RMS patients, a patient case demonstrating why patients may experience increasing disability, and key data on MAYZENT®(siponimod), the first and only oral disease-modifying therapy studied and proven to delay disability progression in a more progressed RMS patient population, including active SPMS.

MAYZENT was evaluated in EXPAND—the largest Phase III study of secondary progressive MS (SPMS) patients to date (N=1651), which included a broad range of patients with moderate-to-advanced disability. Dr. West discusses clinical data from EXPAND including data of up to 5 years from a preplanned interim analysis of the EXPAND open-label extension study.